Glenmark Pharmaceuticals said that its subsidiary Glenmark Pharmaceuticals Columbia has acquired exclusive rights to commercialize AstraZeneca’s Pulmicort Respules budesonide inhalation suspension for the treatment of asthma in Columbia. AstraZeneca will manufacture the inhalation suspension and supply the product to Glenmark.
Glenmark Executive VP and Global Head, Business Development, Marco Cerato commented, “We are excited to collaborate with AstraZeneca and ensure continued and increased access of Pulmicort Respules, a high quality essential therapy to Colombian patients suffering from bronchial asthma. It will also help us in strengthening our key therapy area of respiratory medicine, in the region.”
Read the Glenmark Pharmaceuticals press release.
